Amedi.sk
Dovoľujeme si Vás upozorniť, že naša web stránka
je určená iba pre odbornú lekársku verejnosť.
Časopis Cardiology for practice – Článok The TELMISTAR I project – “Monitoring the Effect of Telmisartan and the Fixed Combination of Telmisartan + Amlodipine on the Achievement of Target Values of Systolic and Diastolic Blood Pressure in Slovakia by Specialist Physicians

Cardiology for practice

Reviewed, postgraduate scientific medical journal.
Period 4x per year
1336-3433
Free full text. The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Cardiology for practice
Cardiology for practice
Reviewed, postgraduate scientific medical journal.
Period 4x per year
Predplatné
Téma: Various

The TELMISTAR I project – “Monitoring the Effect of Telmisartan and the Fixed Combination of Telmisartan + Amlodipine on the Achievement of Target Values of Systolic and Diastolic Blood Pressure in Slovakia by Specialist Physicians

Martin Čaprnda, Katarína Novodomská, Ján Farkašovský, Oliver Tlčimuka

Introduction: Arterial hypertension is one of the most important risk factors for cardiovascular diseases. Its diagnosis and treatment belongs to general practitioners as well as specialists. Despite the existence of a number of antihypertensive drugs, many patients are below the blood pressure (BP) target. Telmisartan, as a representative of the angiotensin II receptor antagonist group, is suitable for a wide range of patients with arterial hypertension, both as monotherapy and in combination with other antihypertensive agents. Due to its partial agonist effect on the PPAR-γ receptor its beneficial effects on glycaemia and lipid parameters have also been described.
Objective of the study: The objective of the study was to monitor the effect of telmisartan and the telmisartan + amlodipine fixed combination on the level of systolic and diastolic BP (sBP, dBP), achievement of BP target values and selected metabolic and biochemical parameters in patients below the BP target values.
Patients and methodology: The TELMISTAR I project was conducted in the form of a prospective, non-randomized, open-label study of 6 months duration. The project included a total of 1,438 patients aged 31-91 (604 men and 834 women) who did not reach the BP target values according to ESC/ESH recommendations. At the discretion of the attending physician, they were set up for treatment with telmisartan (group T) or the fixed combination of telmisartan + amlodipine (group TA). Patients were educated about the need to follow ESC/ESH preventive measures, especially non-pharmacological and pharmacological treatment. Blood pressure, lipid levels, blood glucose and safety parameters (ionogram, urea, creatinine) were performed at baseline medical examination and 3 and 6 months later (after the initial examination). The project was supported by a research grant from KRKA.
Results: The mean BP value at study inclusion was 153.55 ± 15.96 / 91.12 ± 10.27 mmHg in the T group, 157.11 ± 15.61 / 92.60 ± 10.06 mmHg in the TA group, and the target systolic BP was achieved in 13.6% (T) patients, respectively 11.0% (TA) patients, diastolic BP 34.2% patients (T) respectively 28.1% (TA) patients.
After 6-month treatment, the T group manifested an average BP decrease of 20.80 / 12.15 mmHg (p<0.001), and in the TA group of 23.03 / 13.15 mmHg (p<0.001), which also led to a systolic BP 57.3% (T) respectively 54.1% (TA) and diastolic BP increase 58.9% (T) respectively 61.9% (TA). There was no significant change in chloride levels and creatinine levels in the patients.
Conclusion: The addition of telmisartan like fixed combination of telmisartan + amlodipine resulted in a significant decrease in BP, as well as an in an increase in the number of patients reaching the target BP. No significant changes in safety parameters (potassium, creatinine) were observed in patients. An improvement in the lipid profile (decrease in total and LDL cholesterol and triacylglycerols) was also observed in the patients. Telmisartan as a stand-alone medicine and also in the fixed combination of telmisartan + amlodipine is an effective and safe antihypertensive suitable for use in a wide variety of arterial hypertension patients.

arterial hypertension, telmisartan, fixed combination, target values, blood pressure, adherence
Kardiol. Prax 2019; 17 (3): 169-175

Ročník 2019  Témy časopisu Cardiology for practice 3 / 2019

THEME SECTION

Ivana Šoóšová
Andrea Andrášová
Branislav Líška, Jozef Pacák, Ján Postulka, Viliam Fridrich, Pavol Chňupa, Eva Goncalvesová, Ingrid Olejárová
Rudolf Uhliar
Monika Čáni, Júlia Lucká, Tibor Malacký
Stanislava Remišová
Peter Solík

Overview works

Svetlana Bodíková, Veronika Pokorná
Veronika Jankovičová

Case studies

Diana Poláková, Pavol Murín, Mikuláš Szakács

Various

Martin Čaprnda, Katarína Novodomská, Ján Farkašovský, Oliver Tlčimuka
1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
2
Ideal candidate for primary prevention of sudden cardiac death with implantable cardioverter-defibrillator
Cardiac AL Amyloidosis In a 53-year-old Woman
Peripartum Cardiomyopathy
Postablation recurrence of paroxysmal tachycardia – what next?
Left ventricular assist device implantation as a bridge to candidacy (case report)
Pulmonary arteriovenous malformations
Echocardiography in aortic stenosis
STEMI: Possibilities of reperfusion treatment
STEMI management in Slovakia
Kawasaki disease from the cardiologist view
Sudden cardiac death: definition, epidemiology and reality
Patient management after a ICD discharge
Outpatient interventional procedures in cardiology – yes or no?
CHAIRMAN OF THE EDITORIAL BOARD
doc. MUDr. Oľga Jurkovičová, CSc.

CHIEF CONSULTANT
prof. MUDr. Robert Hatala, PhD., FESC

MEMBERS OF THE EDITORIAL BOARD
MUDr. Peter Dědič
MUDr. Juraj Dúbrava, PhD., FESC
MUDr. Viliam Fridrich, PhD.
doc. MUDr. Ján Kmec, PhD.
MUDr. Gabriela Kaliská, PhD., FESC
MUDr. Pavol Lesný
MUDr. Monika Kaldarárová, PhD.
MUDr. Peter Margitfalvi
prof. MUDr. Daniel Pella, PhD.
prof. MUDr. Iveta Šimková, CSc., FESC
MUDr. Viera Vršanská, CSc.

PROFESSIONAL EDITOR
MUDr. Juraj Dúbrava, PhD., FESC

EDITOR-IN-CHIEF
Ing. Danica Paulenová
e-mail: paulenova@amedi.sk

GRAPHIC LAYOUT AND TYPESETTING
Lucia Vecseiová
e-mail: dtp@amedi.sk

MARKETING MANAGER
Ing. Dana Lakotová
mobil: 0903 224 625
e-mail: marketing@amedi.sk

ECONOMY AND SUBSCRIPTIONS
Ing. Mária Štecková
telefón: 02/55 64 72 48
mobil: 0911 117 949
e-mail: ekonom@amedi.sk

LANGUAGE PROOFREADING
Mgr. Eva Doktorová

PROOFREADING OF ENGLISH TEXTS
Mgr. Jana Bábelová
SECTIONS

OVERVIEW PAPERS
The latest knowledge on disease and disease groups aetiology, pathogenesis, diagnoses and therapy. Maximum size is 8 pages (font size 12, line spacing 1.5) with maximum five pictures (graphs). In case of more extensive theme elaboration it is possible to divide the paper to several parts after agreement with editorial office. Write the article with emphasis on its practical usage for cardiologists.

CASE STUDY 
Maximum extent is 7 pages. Structuring: summary, introduction, case study, discussion, conclusion, bibliography.

DIAGNOSTIC AND THERAPEUTICAL ALGORITHMS
Diagnosis and therapy processed into tables and schemes, with minimum text, with emphasis on conciseness and clarity.

MISCELLANEOUS
Reaction to overview articles, news in the field of diagnostics, therapy, trial results (maximum 3 pages), reports from professional events, abstracts from scientific work published abroad, not older than 1 year. Maximum extend is 1 page. Write the title of the paper in Slovak/Czech, authors, workplace, than title of the paper in English with full citation.

FROM BORDERLINE OF CARDIOLOGY
Inter sectional theme elaborated complexly, well-arranged, clear (extent up to 8 pages).


MANUSCRIPT ELABORATION

Write the paper on computer in any common text editor.
- write full length of lines (do not use ENTER at the end of a line)
- do not arrange text into columns
- do not do page make-up, put tables at the end of the paper
- distinguish precisely numbers 1, 0 and letters l, O
- use always parentheses ( )
- explain abbreviations always when first used


MANUSCRIPT REQUIREMENTS

1. An accurate paper title, names and surnames of all authors including academic titles, authors` workplace. The first author address including the phone number, fax and e-mail address.
2. Summary - concise content summary in the extent maximum 10 lines (only at overview papers, case studies from borderline of cardiology). Write in 1st or 3rd person singular or plural (unify according the type of an article).
3. Key words - in the extent of 3-6 (just at overview papers, From borderline of cardiology).
4. English translation: paper title, summary, key words (only at overview papers, case studies and From borderline of cardiology)
5. Text
If you insert pictures into a document, send also their original files in "jpg" format, create graphs in Excel and send also their original files. If you send photo documentation via post office, please, send just high-class originals. Mark each original by a number, under which it is mentioned in the text. Write in 1st or 3rd person singular or plural (unify according the type of an article).
6. Bibliography
Citations are numbered chronologically in bold, references in the text are stated by the number of citations in parentheses. Use maximum 30 citations.

Examples of citations:
1. Shaheen NJ, Crosby NA, Bozymski EM, et al. Is there publication bias in the reporting cancer risk in Barrett´ esophagus? Gastroenterology 2000; 119: 333-338.
2. Stenestrand U, Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
3. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
4. Jurkovičová O, Spitzerová H, Cagáň S. Komorové arytmie a náhla srdcová smrť pri akútnom infarkte myokardu. Bratisl Lek Listy 1997; 98: 379-389.
5. Osborne BE. The electrocardiogram of the rat. In: Budden R, Detweiler DK, Zbinden G. The rat electrocardiogram in pharmacology and toxicology. Oxford: Pergamon Press 1981: 15-27.

Do not use dots after first names in citations. Do not use colon but dot after names of authors. Use semi-colon after the year of publishing, colon is before pages. If an author is one, two or three - it is necessary to state all. If there are more than three authors it is necessary to write first three and "et all", in Slovak and Czech citations "a spol."

Due to publishing of autodidactic tests it is necessary to add 4 questions to your article and 4 answers with marking of one correct answer, e.g.:

In which patients, after overcoming of a thromboembolic cerebral or peripheral event, the least suitable catheter closure is foramen ovale patents:
a. a woman before planned pregnancy
b. paroxysmal fibrillation of the atrium
c. aneurysm of the atrium septum
d. origination of an event after cough

The editorial office reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are double reviewed.

All published papers are paid.

Due to practical focus of the journal we would like to ask you write the paper comprehensively, with emphasis on practical use of provided information in out-patient practice of cardiologists, internists and other professionals who deal with cardiovascular medicine.

Send contributions in the e-mail to the address: paulenova@amedi.sk
Period 4x per year
1336-3433
Free full text. The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Cardiology for practice
Cardiology for practice
Reviewed, postgraduate scientific medical journal.
Period 4x per year
Predplatné